It is a big step forward in what has become a highly scrutinised field, with regulation designed to help reduce the incidents of skin cancer in the U.S.
The global sun care market is projected to reach $9 billion by 2015, therefore Skinvisible president and CEO Terry Howlett says it is vital for R&D firms to seek licensees in the US, Canada and globally for sunscreen formulations
"Skinvisible has put forth a concerted effort to maximize the claims for our sunscreens and therefore we can provide consumers with sun protection which is unsurpassed," he explains.
"Our broad spectrum sun care product line, made with either Avobenzone or Tinosorb-S, along with our moisturizing ‘after-sun’ products, are fully developed including accelerated stability and initial production.”
The products in question are all formulated with patent protection and benefits that will resonate with consumers.
The Nevada-based company has developed sunscreens using its patented Invisicare delivery technology which includes sunscreens with SPF 15, 30 and 50, which are the highest SPF allowed by the FDA.
The sunscreens can be labeled with the following claims as Skinvisible’s formulations surpass all the criteria:
- "prevents sunburn, skin cancer and aging due to the sun"
Broad-Spectrum: According to the FDA, in order for a sunscreen to be labeled ‘broad spectrum’ it must prove it protects against both UVA and UVB rays by having an SPF of at least 15 and a critical wave length of at least 370 nm.
- "Water-resistant for 80 Minutes"
Water-Resistant 80 Minutes: The FDA sunscreen water resistant claim requires that a sunscreen must have the same SPF after being in water or sweating for 40 or 80 minutes.
- Unique Patented Technology / Eight-Hour Photostability
Skinvisible was granted a patent from the United States Patent and Trademark Office entitled ‘Sunscreen Composition with Enhanced UVA Absorber Stability and Methods’, based on its Invisicare delivery system specifically for stabilizing avobenzone; and this provides protection until November 2029.